Drugs / PLG0206
PLG0206
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05137314 | Mar 2022 → Mar 2024 | periprosthetic joint infection | Peptilogics | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07214311 | Feb 2026 → Sep 2028 expected | periprosthetic joint infection | Peptilogics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 11
| Date | Issuer | Release |
|---|---|---|
| 2023-09-18 | Peptilogics | Results Peptilogics Reports Positive 180-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients with Periprosthetic Joint Infection (PJI) peptilogics.com ↗
Peptilogics, a clinical-stage biotechnology company, today announced new top-line interim data for PLG0206 in periprosthetic joint infection (PJI) patients from their ongoing Phase 1b trial. |
| 2023-05-23 | Peptilogics | Results Peptilogics Reports Positive 90-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients with Periprosthetic Joint Infection (PJI) peptilogics.com ↗ |
| 2022-10-19 | Peptilogics | Results Peptilogics to Present Data at IDWeek 2022 on PLG0206, an Engineered Antimicrobial Peptide Targeting Bacteria Causing Periprosthetic Joint Infection peptilogics.com ↗
The studies demonstrate the potent activity of PLG0206 against bacteria that cause periprosthetic joint infections (PJI), including multidrug resistant (MDR) bacteria. |
| 2022-10-06 | Peptilogics | Results Peptilogics Presents Data Demonstrating Antimicrobial Activity Against Difficult to Treat Bacterial Pathogens of Engineered Peptide PLG0206 at the 2022 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance peptilogics.com ↗
Results demonstrate that PLG0206 was active against all tested isolates and retained activity against multi-drug resistant (MDR) strains, suggesting that the unique mechanism of action of PLG0206 can overcome the drug-resistance mechanisms found in these MDR strains. |
| 2022-07-19 | Peptilogics | Regulatory Peptilogics Receives FDA Fast Track Designation for PLG0206, an Investigational Peptide Therapeutic in Development for the Treatment of Periprosthetic Joint Infection peptilogics.com ↗
Peptilogics, a biotech company engineering peptide therapeutics to improve the treatment landscape for patients with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s lead drug candidate, PLG0206, for the treatment of periprosthetic joint infection (PJI). |
| 2022-04-19 | Peptilogics | Results Peptilogics to Present Data Highlighting Designed Antimicrobial Peptide for the Treatment of Periprosthetic Joint Infection (PJI) at ECCMID 2022 peptilogics.com ↗
The preclinical data presented at ECCMID demonstrate that PLG0206 has a low propensity for resistance development and reinforces its broad-spectrum activity against bacteria such as ESKAPE pathogens for the treatment of PJI. |
| 2022-03-30 | Peptilogics | Regulatory Peptilogics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Trial of PLG0206 in Periprosthetic Joint Infection peptilogics.com ↗ |
| 2022-03-30 | Peptilogics | Results Peptilogics Announces Two Peer-Reviewed Publications on Designed Peptide Therapeutic PLG0206 for Periprosthetic Joint Infection peptilogics.com ↗
The data indicated that PLG0206 was safe, well-tolerated and exhibited linear pharmacokinetics (PK) in healthy subjects at doses ranging from 0.05 to 1 mg/kg. |
| 2022-03-22 | Peptilogics | Results Peptilogics’ Presentations at American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting Highlight Peptide Therapeutic PLG0206 for the Treatment of Periprosthetic Joint Infection (PJI) peptilogics.com ↗
The preclinical data showed that PLG0206 reduced biofilm mass and increased survival of animals infected with multi-drug resistant ESKAPE pathogens for the treatment of periprosthetic joint infection (PJI). |
| 2021-11-09 | Peptilogics | Results Peptilogics Presents Positive First-in-Human Phase 1 Data for its Lead Engineered Antibacterial Peptide, PLG0206, at IDWeek 2021 peptilogics.com ↗
The first-in-human trial showed that PLG0206 intravenously administered was well tolerated in healthy volunteers, with linear PK over the dose range. |
| 2021-11-09 | Peptilogics | Results Peptilogics Announces Successful Completion of Phase 1 Clinical Trial of PLG0206, a First-in-Class Anti-Infective Peptide Therapy peptilogics.com ↗ |
All press releases naming this drug 15 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLG0206 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05137314 ↗ |
| Known as | Peptide wlbu-2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315035 ↗ |
| Known as | WLBU-2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315035 ↗ |
| Modality | Peptide | “PLG0206 is an engineered antibacterial peptide (EAP)” NCT05137314 ↗ |
| Route | Other | “administered intraoperatively by local irrigation” NCT05137314 ↗ |